
Supplementary 1. Number of Patients newly prescribed Medicinal Cannabis as reported by TGA's Authorised Prescriber Scheme.



^{*}Authorised Prescribers – Medical Practitioners approved by a HREC or endorsed by a specialist college to prescribe medicinal cannabis

Source: TGA. Medicinal Cannabis Authorised Prescriber Scheme data. Australian Government Therapeutic Goods Administration (TGA) 2023. Accessed September 07, 2023.

<a href="https://www.tga.gov.au/products/unapproved-therapeutic-goods/medicinal-cannabis-hub/medicinal-cannabis-access-pathways-and-patient-access-data/medicinal-cannabis-authorised-prescriber-scheme-data

Supplementary 2. PICO framework with keyword elements, inclusion, and exclusion criteria.

		Keyword elements	Inclusion	Exclusion
Population	Countries allowing therapeutic usage of cannabis, prescribed or otherwise**	 Cannabis and cannabis- based products Medical and therapeutic 	Studies reporting on monitoring of cannabis use as a medicine for aforementioned indications.	Studies reporting on: - Monitoring of recreational cannabis use Synthetic Cannabinoid Receptor Agonists
Intervention	Systems for monitoring of side effects and adverse events	3. Monitoring systems4. Side effects and adverse events	Systems for monitoring of side effects and adverse events mentioned as a core component of the title or abstract.	Small scale surveys as a monitoring system Studies relating to addictive potential of medicinal cannabis Studies focusing on monitoring of adverse effects on social wellbeing (marriage, behaviour, academic achievement)
Comparison	No established monitoring system	N/A	N/A	N/A
Outcome	Integration of formalized monitoring systems into clinical practice (workflow)	5. Pharmacovigilance	N/A	N/A
Study design	Peer-reviewed systematic reviews, scoping reviews, meta-analyses and narrative reviews, primary papers, grey literature	N/A	Papers published from Jan 2015 until June 2023.	Papers not published in English. Animal studies Poster presentations Letters to the editor

^{**}Usage for the following indications: Chronic pain, cancer pain, epilepsy, neuropathic pain in MS, AIDS wasting syndrome, chemotherapy-induced nausea and vomiting, sleep disorders/insomnia, psychiatric disorders (PTSD, schizophrenia), inflammatory conditions such as rheumatoid arthritis (RA), Tourette's, irritable bowel syndrome (IBS), Parkinson's disease, dystonia, glaucoma, ADHD, autism.

Supplementary 3. Categories of searches in search strategy.

Category 1 - Cannabis, Medical, Monitoring Systems and Side Effects Keyword Elements									
Cannabis search terms	Medical Keyword search terms	Monitoring system search terms	Side Effects and Adverse Events search terms						
Cannabi* OR tetrahydrocannabinol OR THC OR delta9* OR nabiximol* OR dronabinol* or Cannabigerol* OR CBG OR CBN OR marijuana OR marihuana.	Therap* OR medic* OR prescrib* OR prescrip* OR treat*	Surveillance OR post marketing, safety, database, registry, registries, OR monitoring	Side effect* OR adverse effect* OR adverse outcome* OR adverse event*						
Category 2 - Cannabis, Medical, Monitoring Systems and Pharmacovigilance Keyword Elements									
Cannabis search terms	Medical search terms	Monitoring search terms	Pharmacovigilance search terms						
Cannabi* OR tetrahydrocannabinol OR THC OR delta9* OR nabiximol* OR dronabinol* or Cannabigerol* OR CBG OR CBN OR marijuana OR marihuana.	Therap* OR medic* OR prescrib* OR prescrip* OR treat*	Surveillance OR post marketing, safety, database, registry, registries, OR monitoring	Pharmacovigilance						

Supplementary 4 Full electronic search strategy for OVID-Embase Category 1 search

- exp postmarketing surveillance/ or exp drug safety/
- 2. exp pharmacovigilance/ or exp drug surveillance program/
- 3. exp drug monitoring/
- 4. ("surveillance" or "post marketing" or "safety" or "database*" or "registry" or "registries" or "monitoring").ti,ab,kf.
- 5. 1 or 2 or 3 or 4
- 6. exp medical cannabis/ or exp cannabis derivative/ or exp "Cannabis sativa subsp. indica"/ or exp cannabis-induced psychosis/ or exp "Cannabis (genus)"/ or exp cannabis smoking/ or exp cannabis or exp "Cannabis sativa subsp. sativa"/ or exp "cannabis use"/
- 7. cannabinol/ or cannabinol derivative/ or exp cannabis/ or exp cannabinoid/ or "cannabis (genus)"/ or cannabis addiction/ or cannabis derivative/
- 8. ("cannabir" or "tetrahydrocannabinol" or "THC" or "delta9*" or "nabiximol*" or "dronabinol*" or "cannabigerol*" or "CBG" or "CBN" or "marijuana" or "marijuana").ti,ab,kf.
- 9. 6 or 7 or 8
- 10. exp drug therapy/ or exp therapy/
- 11. ("therap*" or "medic*" or "prescrib*" or "prescrip*" or "treat*").ti,ab,kf.
- 12 10 or 1
- 13. exp side effect/dm, si [Disease Management, Side Effect]
- 14. exp adverse event/ or exp adverse drug reaction/
- 15. ("side effect*" or "adverse effect*" or "adverse outcome*" or "adverse event*").ti,ab,kf.
- 16. 13 or 14 or 15
- 17. 5 and 9 and 12 and 16
- 18. limit 17 to yr="2015 2023"

Category 2 search

- 1. exp postmarketing surveillance/ or exp drug safety/
- 2. exp drug surveillance program/ or exp drug monitoring/
- 3. ("surveillance" or "post marketing" or "safety" or "database*" or "registry" or "registries" or "monitoring").ti,ab,kf.
- 4. 1 or 2 or 3
- 5. exp pharmacovigilance/
- 6. pharmacovigilance.ti,ab,kf.
- 7. 5 or 6
- exp medical cannabis/ or exp cannabis derivative/ or exp "Cannabis sativa subsp. indica"/ or exp cannabis-induced psychosis/ or exp "Cannabis (genus)"/ or exp cannabis smoking/ or exp cannabis/ or exp "Cannabis sativa subsp. sativa"/ or exp "cannabis use"/
- 9. cannabinol/ or cannabinol derivative/ or exp cannabis/ or exp cannabinoid/ or "cannabis (genus)"/ or cannabis addiction/ or cannabis derivative/
- 10. ("cannabit" or "tetrahydrocannabinol" or "THC" or "delta9*" or "nabiximol*" or "dronabinol*" or "cannabigerol*" or "CBG" or "CBN" or "marijuana" or "mar
- 11. 8 or 9 or 10
- 12. exp drug therapy/ or exp therapy/
- 13. ("therap*" or "medic*" or "prescrib*" or "prescrip*" or "treat*").ti,ab,kf.
- 14. 12 or 13
- 15. 4 and 7 and 11 and 14
- 16. limit 15 to yr="2015 2023"

Supplementary 5. Monitoring systems included in primary papers

Author/Date	Italian Phytovigilance Database	German Pain E- registry	Quebec Cannabis Registry	The Registry	Australian Emyria Clinical e- Registry	FAERS	UKMCR	ToxiC registry	Vigibase	SwissCan On	Health Canada	Eudravigi lance	TGA	AMK	AIFA	Project 21
Sakal et al. 2021 ⁷⁹																
Patti et al. 2016 ⁷⁷																
Guevara et al. 2015 ⁴⁶																
Obrien et al. 2023 ⁷⁸																
Messina et al. 2017 ⁷⁶																
Lynskey et al. 2022 ⁶⁸																
Ammendoliaetal.2023 ⁴⁹																
Aprikianetal.2023 ³⁹																
Cresciolietal.2020 ²⁸																
Dalavayeetal.2023 ⁶¹																
Ergisietal.2022 ⁶³																
Ergisietal.2023 ⁵²																
Erridgeetal.2022 ⁵⁸																
Erridgeetal.2022 ⁵⁶																
Erridgeetal.2021 ⁵⁰																
Etgesetal.2016 ⁴⁵																
vanHunseletal.202243																
Freudewaldetal.2022 ⁶⁹																
Jacketal.2022 ⁴⁷																
Kawkaetal.2021 ⁶⁰																
Rhyeeetal.2018 ⁷³																
Loveetal.2022 ⁷²																
Lunghietal.2022 ³⁵																
Harrisetal.2022 ⁶⁶																

				I				
Mangooetal.2022 ⁵⁵								
Morideetal.2022 ⁴⁰								
Nicholasetal.2023 ⁶⁴								
Nimalanetal.2022 ⁶⁷								
Olssonetal.2023 ⁵¹								
Pillaietal.2022 ⁵⁴								
Pochetetal.2022 ⁴⁴								
PrietoGonzalezetal.2021								
Pirachaetal.2017 ³⁷								
Rifkin-Zybutzetal.2023 ⁵⁷								
Holveyetal.2023 ⁶⁵								
Jacketal.2022 ²⁹								
Sharmaetal.2020 ³⁸								
Spyresetal.2020 ⁷¹								
Spyresetal.2015 ⁷⁰								
Simonetal.2023 ³⁶								
Taitetal.2023 ⁵⁹								
Taitetal.2023 ⁶²								
TGA,2023. ⁷⁴								
Trojanetal.2022 ⁷⁵								
Ueberalletal.2019 ³¹								
Ueberalletal.2022 ³²								
Ueberalletal.2022 ³⁰								
Ueberalletal.2022 ³⁴								
Vickeryetal.2022 ⁴⁸						 		
Viganoetal.2020 ⁴¹								
Viganoetal.2022 ⁴²								
Wangetal.2023 ⁵³								

Supplementary 6. Differences between databases and registries.

Characteristics	Database	Registry
Purpose	Often designed for multiple uses rather than only monitoring therapeutics	Designed with a specific purpose in mind, such as monitoring of effectiveness or safety
Data structure	Includes various data types, such as patient information, clinical trials data, and pharmacological details	Simpler and designed for a specific aim (i.e tracking patient outcomes over time for a specific condition or treatment)
Flexibility	May offer more flexibility, allowing complex queries that can filter several data types	Limited querying capabilities tailored to the specific data it collects
Ownership	Typically owned and created by the same institution	Owned by a variety of organizations but are often initiated by health agencies, research, or medical organisations
Data Sources	Multi-purpose, and can include both research and clinical data	Sources data directly from clinicians, patients, or specific clinical studies.
Updates	If not designed for real time monitoring, may not be regularly updated	Regularly updated for longitudinal monitoring
Scope	Wider in scope, not limited to a specific therapeutic area or patient population	Narrower in scope, focusing on a specific therapy or patient population.

Supplementary 7. Reporting hierarchy of side effects and adverse events associated with CBM usage

